PEG-Bio Biopharm

Recent papers from PEG-Bio Biopharm

1. Reprogramming Enfumafungin Biosynthesis for High-Titer Production in the Endophytic Fungus Hormonema carpetanum ATCC 74360ACS Synthetic Biology · 2026
2. Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 studyThe Lancet Regional Health - Western Pacific · 2024
3. Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201CPT Pharmacometrics & Systems Pharmacology · 2023
4. A Single‐dose, Two‐Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese SubjectsClinical Pharmacology in Drug Development · 2023
5. A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB ‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocolDiabetes Obesity and Metabolism · 2022
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trialEClinicalMedicine · 2021
7. Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled studyDiabetologia · 2021
8. A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019The Journal of Infectious Diseases · 2020
9. Screening technologies for recombinant antibody librariesMedical Research Archives · 2015
10. Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activityBritish Journal of Pharmacology · 2011